RAB35 and lung carcinoma: Moreover, biological database (http://kmplot.com/analysis/) exhibited the relationship between RAB35 expression and survival cycle in 1928 lung cancer patients, indicating that the median survival of patients with RAB35 low expression was 99.43 months, while that of patients with RAB35 high expression was only 53 months (Figure 4B).